Researchers uncover why typically normal protein drives prostate cancer

NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.

Scientists reclassify 200 rare immune system disorders using network-based approach

Scientists at CeMM, Max Perutz Labs, and St. Anna Children’s Cancer Research Institute in Vienna have achieved a significant advancement in the research of rare

September 2, 2023

EphrinB2 Expression in Urothelial Cancer Tied to Checkpoint Inhibitor Activity

A prior analysis of data from The Cancer Genome Atlas (TCGA) demonstrated that high EphrinB2 gene expression was associated with poor survival in patients with

July 6, 2023

NS Pharma asset gains FDA rare paediatric disease status

NS Pharma’s NS-089/NCNP-02 (brogidirsen) is intended for patients with Duchenne muscular dystrophy. Credit: Jose Luis Calvo via Shutterstock.com. The US Food and Drug Administration (FDA) has

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.